The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
A Comparison of Budesonide with Prednisolone for Active Crohn's Disease
Open accessAbstract
BACKGROUND: Patients with active Crohn's disease are often treated with corticosteroids, but the treatment has many side effects. Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism in the liver, its systemic bioavailability is low. METHODS: We conducted a randomized, double-blind, 10-week trial comparing the efficacy and safety of an oral controlled-release form of budesonide with the efficacy and safety of prednisolone in 176 patients with active ileal or ileocecal Crohn's disease (88 patients in each treatment group). The dose of budesonide was 9 mg per day for eight weeks and then 6 mg per day for two weeks. The dose of prednisolone was 40 mg per day for two weeks, after which it was gradually reduced to 5 mg per day during the last week. RESULTS: At 10 weeks, 53 percent of the patients treated with budesonide were in remission (defined as a score < or = 150 on the Crohn's disease activity index), as compared with 66 percent of those treated with prednisolone (P = 0.12). The mean score on the Crohn's disease activity index decreased from 275 to 175 in the budesonide group and from 279 to 136 in the prednisolone group (P = 0.001). Corticosteroid-associated side effects were significantly less common in the budesonide group (29 vs. 48 patients, P = 0.003). Two patients in the prednisolone group had serious complications (one had intestinal perforation and one an abdominal-wall fistula). The mean morning plasma cortisol concentration was significantly lower in the prednisolone group than in the budesonide group after 4 weeks (P < 0.001) and 8 weeks (P = 0.02) of therapy, but not after 10 weeks. CONCLUSIONS: Among patients with active Crohn's disease, both controlled-release budesonide and prednisolone are effective in inducing remission. In this trial, prednisolone reduced scores on the Crohn's disease activity index more, whereas with budesonide there were fewer glucocorticoid-associated side effects and less suppression of pituitary-adrenal function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 563
Self-citationMesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
Singleton, J. W., Hanauer, S. B., Gitnick, G. L., Peppercorn, M. A., Robinson, M. G., Wruble, L. D., & Krawitt, E. L. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90337-c · Cited by 357
Heath, D. I., Cruickshank, A., Gudgeon, M., Jehanli, A., Shenkin, A., & Imrie, C. W. (1993) · Gut · doi:10.1136/gut.34.1.41 · Cited by 290
Brogden, R. N., & McTavish, D. (1992) · Drugs · doi:10.2165/00003495-199244030-00007 · Cited by 176
Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel Disease
Brattsand, R. (1990) · Canadian Journal of Gastroenterology · doi:10.1155/1990/708916 · Cited by 153
Cited by
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422202 · Cited by 727
Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Löfberg, R., Modigliani, R., Present, D. H., Rutgeerts, P., Schölmerich, J., Stange, E. F., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.31072 · Cited by 686
Self-citationTravis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., D’Haens, G., Kitis, G., Cortot, A., Prantera, C., et al. (2006) · Gut · doi:10.1136/gut.2005.081950b · Cited by 597
Oral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 563
Self-citation
Metadata
- Authors
- Rutgeerts, P., Lofberg, R., Malchow, H., Lamers, C., Olaison, G., Jewell, D., Danielsson, A., Goebell, H., Thomsen, O. O., Lorenz-Meyer, H., Hodgson, H., Persson, T., & Seidegard, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-09-29
- Volume
- 331
- Issue
- 13
- Pages
- 842-845
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2342066803
- Cited by
- 589
- References
- 13
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison of Budesonide with Prednisolone for Active Crohn's Disease. https://app.cochat.ai/papers/10.1056/nejm199409293311304
- The paper
- Rutgeerts, P., Lofberg, R., Malchow, H., Lamers, C., Olaison, G., Jewell, D., Danielsson, A., Goebell, H., Thomsen, O. O., Lorenz-Meyer, H., Hodgson, H., Persson, T., & Seidegard, C. (1994). A Comparison of Budesonide with Prednisolone for Active Crohn's Disease. New England Journal of Medicine. https://doi.org/10.1056/nejm199409293311304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.